This medicine is an impressive collection of firsts: not only is it the first drug approved to treat lupus, a potentially fatal disease in which the immune system attacks healthy tissues, it is also one of the first drugs to come out of genomics, the systematic evaluation of human genetics that was epitomized by the human genome project a decade ago.
As a retirement coach for ING Financial Partners, Ms. Kylen has seen many an investor reduced to tears at the mere thought of losing money on an investment or running out of funds in retirement so many that she keeps a big box of tissues on her desk.